ArticleResearch square2026
Synaptojanin1 regulates synaptic dopamine release and axonal integrity via retromer-dependent endosomal sorting.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Synaptic dysfunction is increasingly recognized as an early feature of Parkinson's disease (PD); however, synaptic mechanisms contributing to early dopamine release defects and neurodegeneration remains poorly understood. Here we identify a presynaptic endosomal-dependent mechanism supporting dopamine release and axonal integrity. Loss of the PD-associated lipid enzyme Synaptojanin1 impairs dopamine release due to endosomal retention of the dopamine D2 autoreceptor and dopamine transporter (DAT). Conditional deletion of Synaptojanin1 in mouse dopamine neurons results in endosomal swelling within striatal DAT clusters and PD-like locomotor deficits. Mechanistically, Synaptojanin1 remodels endosomal phosphatidylinositol 4-phosphate to facilitate the recruitment of the PD-associated retromer component VPS35. Notably, overexpressing VPS35 rescues presynaptic sorting defects in Synaptojanin1-deficient dopamine neurons despite lipid impairments. Furthermore, Synaptojanin1 and VPS35 exhibit correlated expression and dopamine-induced co-clustering in axons, supporting their broader roles in regulating synaptic surface proteins. Our work demonstrates a lipid-dependent endosomal mechanism that may contribute to motor deficits in early PD.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.